Glucotrack Advances Diabetes Management with Novel Continuous Blood Glucose Monitor
TL;DR
Glucotrack, Inc. achieves a breakthrough in diabetes management with the first multi-year continuous glucose monitoring system, giving a competitive edge in precision and longevity.
The Continuous Blood Glucose Monitor (CBGM) from Glucotrack measures glucose levels directly in the blood, eliminating accuracy limitations and the hassle of frequent sensor changes.
Glucotrack's CBGM offers a leap forward in diabetes care, providing accurate, real-time data for treatment decisions and reducing the burden on patients, potentially improving their quality of life.
The CBGM system from Glucotrack revolutionizes glucose monitoring with direct blood measurement, significant maintenance reduction, and unparalleled sensor longevity, marking a transformative evolution in diabetes care.
Found this article helpful?
Share it with your network and spread the knowledge!
Diabetes management could be on the cusp of a significant transformation as Glucotrack successfully completes its first human clinical trial for a revolutionary Continuous Blood Glucose Monitor (CBGM). The new device offers potential breakthrough solutions to longstanding challenges in glucose monitoring, including direct blood measurement, reduced maintenance, and unprecedented sensor longevity.
The clinical trial, conducted over four days with six diabetes patients, validated the safety and feasibility of the CBGM system. Researchers focused on assessing the procedural simplicity of implanting and removing the sensor lead, with no procedure- or device-related serious adverse events reported.
Unlike current continuous glucose monitors that measure interstitial fluid and require frequent sensor replacements, Glucotrack's CBGM directly measures blood glucose levels. The system promises a three-year sensor life, compared to existing technologies that require replacements every 10 to 15 days. This innovation could significantly reduce the management burden for patients with diabetes.
The continuous glucose monitoring market is projected to reach $11.5 billion in annual revenue by 2024, with an expected growth rate of 7.19% annually. Current market leaders like Dexcom Inc and Abbott Laboratories have highlighted the need for more advanced monitoring solutions that address accuracy and convenience challenges.
While this initial study did not measure sensor accuracy, Glucotrack reported that the system performed consistently with preclinical animal studies. The trial was performed by interventional cardiologists, which could facilitate future clinical workflow integration.
The successful trial marks a critical transition from conceptual development to real-world application. Glucotrack plans to expand clinical testing, pursue regulatory approvals, and advance commercialization efforts. The company intends to present its findings at an upcoming diabetes conference, potentially signaling a new era in diabetes care technology.
Curated from NewMediaWire
